Thousands of Australians with multiple sclerosis have been spared paying $33,000 a year for treatment after the federal government struck a deal to keep life-changing drugs on the Pharmaceutical Benefits Scheme.
Health Minister Mark Butler has confirmed drugs including Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain listed on the PBS while an urgent review of MS medicines is carried out, easing weeks of anxiety for patients, their families and clinicians.